Testing lower doses of JAK inhibitors for rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have rheumatoid arthritis that meets standard medical criteria.
- You must have been taking a full dose of a JAK inhibitor for at least 6 months.
- Your disease must be well controlled (low disease activity) for at least 6 months.
- You must not have had a flare-up in the last 6 months.
- You must not be taking certain other arthritis medications like biologics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if reducing the dose of a JAK inhibitor can keep your inflammatory arthritis under control. If you have rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis and are in a stable remission, you may be able to take a lower dose.
This trial tests taking a JAK inhibitor (a type of pill that helps calm inflammation in rheumatoid arthritis) by mouth. It aims to see how well it works and if it's safe for people with RA who need this kind of medicine.
This study compares two oral medications, tofacitinib and upadacitinib, when added to methotrexate for people with rheumatoid arthritis. The goal is to see which one works better and is safer for controlling symptoms.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This study tests whether combining two medicines, iguratimod and tofacitinib, works better than taking either alone for people with rheumatoid arthritis whose symptoms are not well controlled by their current treatment. If you join, you might get both drugs together to see if it helps reduce pain and swelling.
Hear when a new Rheumatoid Arthritis (RA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.